Emily Drabant Conley, Ph.D., is Chief Executive Officer of Federation Bio. Federation Bio is pioneering a new modality for treating intractable diseases that harness microbes’ power and transforms them into cell therapy. Federation Bio’s naturally occurring, metabolically complete bacterial communities are designed to maximize therapeutic potential and durably engraft in patients. Previously, Dr. Conley spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As Vice President of Business Development at 23andMe, she architected visionary partnerships across pharma and biotech.
Dr. Conley was named one of the 30 Leaders Under 40
who are transforming US healthcare by Business Insider and one of the 25 women shaping technology’s future by Google Ventures.
She currently serves on TMRW and Medrio and formerly served on the board of Lesbians Who Tech and the UCSF Alliance Health Project.
Before moving into the industry, Dr. Conley spent 10 years in academia conducting genetics research. She was a research fellow at the National Institutes of Health and is a co-author of more than 35 academic publications. She received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. She graduated summa cum laude from Vanderbilt University with a B.A.